Ibrutinib sustains efficacy in CLL at 4-year follow-up

Print Friendly, PDF & Email


Ibrutinib (Imbruvica)
Photo courtesy of Janssen
The 4-year follow-up of the RESONATE trial suggests ibrutinib may provide long-term efficacy in previously treated patients with chronic lymphocytic leukemia (CLL). The median progression-free survival (PFS) has not yet been reached in this trial, regardless of high-risk cytogenetics, according to Jennifer Brown, MD, PhD, of the Dana-Farber... [Read Article]
Print Friendly, PDF & Email

BCMA emerging as a promising target in MM

Print Friendly, PDF & Email


Bone marrow aspirate showing plasma cells of multiple myeloma
The B-cell maturation antigen (BCMA) is emerging as a promising target in multiple myeloma (MM), according to Adam D. Cohen, MD, of the University of Pennsylvania in Philadelphia. BCMA is highly expressed on MM cells and, with its 2 ligands, is responsible for maintaining... [Read Article]
Print Friendly, PDF & Email

Speaker advises caution in adding mAbs upfront in MM

Print Friendly, PDF & Email


Joseph Mikhael, MD
Photo courtesy of Mayo Clinic
Despite the attraction of incorporating monoclonal antibodies (mAbs) into upfront therapy for multiple myeloma (MM), a speaker at Lymphoma & Myeloma 2017 suggested mAbs are “not quite ready” for this use. MAbs, particularly daratumumab, have shown single-agent activity in refractory MM and have been feasibly... [Read Article]
Print Friendly, PDF & Email

X-GEM finds drug to have economic value in MM

Print Friendly, PDF & Email


Bone fracture
Investigators have developed a model that suggests the clinical benefits of denosumab translate into economic value. The investigators designed their model, X-GEM (Exgeva-Global Economic Model), using results from a large multiple myeloma (MM) trial that showed denosumab to be non-inferior to zoledronic acid (ZA) for skeletal-related events (SRE). Noopur S. Raje, MD,... [Read Article]
Print Friendly, PDF & Email